文献速递乳腺CTMR

术前增强锥形束乳腺CT评估新辅助化疗后残留肿瘤的准确性:与乳腺MRI的对比研究

Accuracy of Preoperative Contrast-enhanced Cone Beam Breast CT in Assessment of Residual Tumor after Neoadjuvant Chemotherapy: A Comparative Study with Breast MRI.
PubMed 文献 · Acad Radiol · 2023-01-06

本研究对比了术前增强锥形束乳腺CT(CE-CBBCT)与MRI在新辅助化疗(NAC)后评估残留肿瘤的准确性,纳入91例女性患者。CE-CBBCT与病理的一致性良好(ICC=0.64),MRI为中等(ICC=0.59),且CE-CBBCT高估程度更小(中位0.24 cm vs. 0.67 cm,p=0.000)。在预测病理完全缓解(pCR)方面两者性能相当(AUC 0.749 vs. 0.733,p>0.05)。CE-CBBCT可作为NAC术后术前评估的替代方法。

要点

  • CE-CBBCT评估残留肿瘤大小与病理一致性良好,优于MRI。
  • CE-CBBCT对残留DCIS、钙化及luminal亚型显示更优准确性。
  • CE-CBBCT与MRI预测pCR性能相当,可作为替代方法。

核心结论

  • CE-CBBCT在评估NAC后残留肿瘤方面准确性优于MRI,尤其在含残留DCIS、钙化及luminal亚型时。
  • CE-CBBCT预测pCR的性能与MRI相当。
  • CE-CBBCT可作为NAC术后术前评估的替代方法。

研究设计与样本

  • 单中心回顾性研究,纳入91例女性乳腺癌患者。
  • 所有患者在新辅助化疗后、术前接受CE-CBBCT和MRI检查。
  • 以病理结果为参考标准,采用ICC评估肿瘤大小一致性,计算AUC、敏感度、特异度、PPV、NPV比较pCR预测性能。

诊断标准与关键数值

  • CE-CBBCT与病理的ICC=0.64(95% CI,0.35-0.78),MRI的ICC=0.59(95% CI,0.36-0.77)。
  • CE-CBBCT高估肿瘤大小的中位差值为0.24 cm(IQR 0.00-1.31),MRI为0.67 cm(IQR 0.00-1.81),p=0.000。
  • 预测pCR的AUC:CE-CBBCT 0.749,MRI 0.733,p>0.05。
  • 亚组分析:含残留DCIS(p=0.000)、钙化(p=0.000)、luminal A(p=0.043)、luminal B(p=0.009)时CE-CBBCT准确性优于MRI。

临床应用与阅片要点

  • 对于NAC术后评估残留肿瘤,可考虑使用CE-CBBCT作为MRI的替代或补充。
  • 当怀疑残留DCIS、钙化或luminal亚型时,CE-CBBCT可能提供更准确的肿瘤大小评估。
  • CE-CBBCT高估肿瘤大小的程度小于MRI,有助于更准确的手术规划。

局限性

  • 单中心研究,样本量有限(91例),结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To compare the accuracy of preoperative contrast-enhanced cone beam breast CT (CE-CBBCT) and MRI in assessment of residual tumor after neoadjuvant chemotherapy (NAC).

MATERIALS AND METHODS: Residual tumor assessments in 91 female patients were performed on preoperative CE-CBBCT and MRI images after NAC. The agreements of tumor size between imaging and pathology were tested by Intraclass Correlation Coefficient (ICC). Subgroup analyses were set according to ductal carcinoma in situ (DCIS), calcifications and molecular subtypes. Correlated-samples Wilcoxon Signed-rank test was used to analyze the difference between imaging and pathology in total and subgroups. AUC, sensitivity, specificity, PPV, and NPV were calculated to compare the performance of CE-CBBCT and MRI in predicting pathological complete response (pCR).

RESULTS: Comparing with pathology, the agreement on CE-CBBCT was good (ICC = 0.64, 95% CI, 0.35-0.78), whereas on MRI was moderate (ICC = 0.59, 95% CI, 0.36-0.77), and overestimation on CE-CBBCT was less than that on MRI (median (interquartile range, IQR): 0.24 [0.00, 1.31] cm vs. 0.67 [0.00, 1.81] cm; p = 0.000). In subgroup analysis, CE-CBBCT showed superior accuracy than MRI when residual DCIS (p = 0.000) and calcifications (p = 0.000) contained, as well as luminal A (p = 0.043) and luminal B (p = 0.009) breast cancer. CE-CBBCT and MRI performed comparable in predicting pCR, AUCs were 0.749 and 0.733 respectively (p > 0.05).

CONCLUSION: CE-CBBCT showed superior accuracy in assessment of residual tumor compared with MRI, especially when residual DCIS or calcifications contained and luminal subtype. The performance of preoperative CE-CBBCT in predicting pCR was comparable to MRI. CE-CBBCT could be an alternative method used for preoperative assessment after NAC.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Zhao, Ma, et al. Accuracy of Preoperative Contrast-enhanced Cone Beam Breast CT in Assessment of Residual Tumor after Neoadjuvant Chemotherapy: A Comparative Study with Breast MRI. Acad Radiol. 2023. PMID: 36610931. doi:10.1016/j.acra.2022.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。